N Zealand to drop Pfizer's Neurontin
This article was originally published in Scrip
Executive Summary
Pharmac, the New Zealand drug subsidy agency, has proposed that Pfizer's antiepilepsy therapy, Neurontin (gabapentin), be dropped from the state-funded pharmaceutical schedule and that Pacific Pharmaceuticals' version be the solely funded product from August 1st.